Maze Therapeutics

IPO

Harnessing the power of genetics to transform the lives of patients

Public · South San Francisco, United States · Founded 2020 · $305.0M raised

Employees
51–200
Founded
2020
Business Model
Other
Website
mazetx.com
Total Funding
$305.0M
Last Round
$115.0M Series DDec 2024
Rounds
2
Type
Public

About

Maze Therapeutics is a clinical-stage biopharmaceutical company using human genetics insights via its Compass platform to develop small molecule precision medicines for kidney and metabolic diseases like APOL1-mediated kidney disease and chronic kidney disease.

Summary

Maze Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2020. It has raised $305.0M in total across 2 rounds, most recently a $115.0M Series D round in Dec 2024. Investors include Frazier Life Sciences, Deep Track Capital and Matrix Capital Management.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOInitial Public OfferingJan 2025
$140.0M

Sign up to see all 3 rounds

Venture Round through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Maze Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/maze-therapeutics"><img src="https://indexed.vc/api/badge/company/maze-therapeutics" alt="Maze Therapeutics on Indexed.vc" width="260" height="76" /></a>